Immatics N.V. (IMTX)

NASDAQ: IMTX · Real-Time Price · USD
5.39
-0.05 (-0.92%)
May 30, 2025, 4:00 PM - Market closed
-0.92%
Market Cap 655.16M
Revenue (ttm) 155.80M
Net Income (ttm) -24.21M
Shares Out 121.55M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 581,853
Open 5.29
Previous Close 5.44
Day's Range 5.29 - 5.61
52-Week Range 3.30 - 13.77
Beta 0.87
Analysts Strong Buy
Price Target 14.67 (+172.17%)
Earnings Date May 13, 2025

About IMTX

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Harpreet Singh
Employees 682
Stock Exchange NASDAQ
Ticker Symbol IMTX
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for IMTX stock is "Strong Buy." The 12-month stock price forecast is $14.67, which is an increase of 172.17% from the latest price.

Price Target
$14.67
(172.17% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

Stafford , Texas and Tuebingen, Germany, May 31, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of...

11 hours ago - GlobeNewsWire

Immatics Announces First Quarter 2025 Financial Results and Business Update

Houston, Texas and Tuebingen, Germany, May 13, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T...

18 days ago - GlobeNewsWire

Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

Houston, Texas and Tuebingen, Germany, April 23, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of...

5 weeks ago - GlobeNewsWire

Immatics N.V.: Trading Below Cash, But Not Without Reason

Immatics' lead asset, IMA203, shows promising early data with a 57% ORR in heavily pretreated patients, but toxicity concerns remain. Financially, IMTX has a $540mn market cap and $628mn cash, but neg...

2 months ago - Seeking Alpha

Immatics Announces Full Year 2024 Financial Results and Business Update

Houston, Texas and Tuebingen, Germany, March 27, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of...

2 months ago - GlobeNewsWire

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME

The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics

6 months ago - GlobeNewsWire

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

Two oral presentations and multiple posters on clinical and preclinical-stage candidates to be presented at SITC, demonstrating the strength of Immatics' TCR-T PRAME franchise to target solid cancers

7 months ago - GlobeNewsWire

Immatics: A Promising TCR Pipeline

Immatics is an early-stage biotech focused on cell-based immunotherapies for solid cancers. Their ACTEngine pipeline shows promise, particularly IMA203/IMA203CD8 targeting the PRAME antigen. Valuation...

8 months ago - Seeking Alpha

Immatics Announces Pricing of $150 Million Public Offering

H ouston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redire...

8 months ago - GlobeNewsWire

Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?

On Thursday, Immatics N.V.  IMTX stock is trading lower after the company commenced an underwritten public offering of $150 million.

8 months ago - Benzinga

Immatics Announces Proposed $150 Million Public Offering

Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirec...

8 months ago - GlobeNewsWire

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST

8 months ago - GlobeNewsWire

Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

Houston, Texas and Tuebingen, Germany, October 4, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development o...

8 months ago - GlobeNewsWire

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

Houston, Texas and Tuebingen, Germany, September 16, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and developmen...

9 months ago - GlobeNewsWire

Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

Houston, Texas and Tuebingen, Germany, September 06, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and developmen...

9 months ago - GlobeNewsWire

Immatics Announces Second Quarter 2024 Financial Results and Business Update

Houston, Texas and Tuebingen, Germany, August 13, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development o...

10 months ago - GlobeNewsWire

Immatics Announces First Quarter 2024 Financial Results and Business Update

Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME

1 year ago - GlobeNewsWire

Immatics: Big Pharma Partners, Intriguing Catalysts Make Buy Case

Immatics, a German biotech company, achieved its Nasdaq listing in 2020 through a merger with Arya Sciences Acquisition Corp, a SPAC sponsored by Perceptive Advisors. The company focuses on developing...

1 year ago - Seeking Alpha

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Houston, Texas and Tuebingen, Germany, March 21, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecti...

1 year ago - GlobeNewsWire

Immatics: Pioneering TCR Therapies In The Fight Against Cancer

Immatics is a significant player in T-cell redirecting cancer immunotherapies, with a clinical-stage pipeline showing promising interim results. The company has formed strategic partnerships with Mode...

1 year ago - Seeking Alpha

Immatics Announces Pricing of $175 Million Public Offering

Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirec...

1 year ago - GlobeNewsWire

Immatics Announces Proposed Public Offering

Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirec...

1 year ago - GlobeNewsWire

Immatics Announces Third Quarter 2023 Financial Results and Business Update

Tuebingen, Germany and Houston, TX, November 14, 2023 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecti...

1 year ago - GlobeNewsWire

Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

Company to host conference call and webcast today, November 8, at 8:30 am EST/2:30 pm CET

1 year ago - GlobeNewsWire

Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy

RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous and uveal melanoma, ovarian cancer and other cancer types Regulatory activities und...

1 year ago - GlobeNewsWire